MedTrace Logo

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

NCT07362030 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-01-23

No results posted yet for this study

Summary

The drug-drug interaction study had been designed to investigate the effect of RAY1225 on the pharmacokinetics of digoxin, Rosuvastatin and

Conditions

Interventions

DRUG

RAY1225

subcutaneous injection

DRUG

atorvastatin calcium tablet

Oral

DRUG

Metformin Tablets

Oral

DRUG

Warfarin Sodium Tablets

Oral

DRUG

Digoxin Tablets

Oral

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-04-14
Primary Completion
2025-12-27
Completion
2026-03-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07362030 on ClinicalTrials.gov